Loading...
XKRX000220
Market cap54mUSD
Jan 10, Last price  
5,000.00KRW
1D
0.40%
1Q
9.05%
Jan 2017
7.64%
Name

Yuyu Pharma Inc

Chart & Performance

D1W1MN
XKRX:000220 chart
P/E
—
P/S
0.59
EPS
—
Div Yield, %
2.47%
Shrs. gr., 5y
2.64%
Rev. gr., 5y
10.55%
Revenues
137.21b
-1.20%
73,393,135,00073,840,117,00045,014,225,00047,900,307,00052,027,334,00058,798,714,33061,984,734,47061,994,114,84062,816,222,71069,743,374,56071,578,932,06062,852,074,31083,096,445,25090,877,644,15098,119,846,400115,655,485,000138,881,056,340137,209,588,670
Net income
-7.18b
L+62.27%
8,558,432,00013,566,114,000-5,687,375,0002,273,392,0001,117,272,0001,906,768,9002,978,726,7901,876,521,870-7,467,373,380-252,675,0805,885,697,4304,541,420,8104,020,291,0704,722,296,7102,412,605,440-920,289,070-4,425,392,920-7,180,899,668
CFO
421m
P
6,801,053,0003,263,836,00013,074,087,0009,407,251,0005,814,628,0006,673,925,2006,510,487,490-775,171,8001,363,384,420-11,683,508,1609,816,265,2901,335,382,2606,110,025,07013,185,371,370-2,669,008,8204,508,660,900-6,229,000,580420,857,130
Dividend
Dec 27, 2023105 KRW/sh

Profile

Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, including osteoporosis, brainbone metabolism-hypocalcemia improvement, cerebral and peripheral circulatory disturbance, tromboembolism, respiratory organ, hypertension, pulmonary tuberculosis therapy, arthrifuge, diabetic neuropathy therapy, eczematous dermatitis drugs, and other circulatory system drugs, as well as antibiotics and skeletal muscle relaxants. It also provides non-prescription drugs and health supplements. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.yuyu.co.kr/ko/main/main.do
IPO date
Nov 18, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑032016‑032015‑03
Income
Revenues
137,209,589
-1.20%
138,881,056
20.08%
Cost of revenue
111,768,970
114,181,801
Unusual Expense (Income)
NOPBT
25,440,618
24,699,256
NOPBT Margin
18.54%
17.78%
Operating Taxes
98,436
615,016
Tax Rate
0.39%
2.49%
NOPAT
25,342,182
24,084,239
Net income
(7,180,900)
62.27%
(4,425,393)
380.87%
Dividends
(2,001,735)
(2,033,747)
Dividend yield
2.33%
1.97%
Proceeds from repurchase of equity
(1,785,236)
BB yield
1.73%
Debt
Debt current
25,386,189
37,424,958
Long-term debt
14,857,429
2,645,227
Deferred revenue
Other long-term liabilities
9,501,573
1,973,690
Net debt
1,022,201
8,287,806
Cash flow
Cash from operating activities
420,857
(6,229,001)
CAPEX
(4,514,389)
(5,567,721)
Cash from investing activities
(2,814,814)
(8,543,848)
Cash from financing activities
7,160,246
(9,083,180)
FCF
18,772,143
13,401,797
Balance
Cash
32,354,182
30,777,637
Long term investments
6,867,235
1,004,741
Excess cash
32,360,938
24,838,325
Stockholders' equity
54,847,380
81,951,386
Invested Capital
136,903,443
139,270,382
ROIC
18.35%
18.86%
ROCE
14.65%
14.72%
EV
Common stock shares outstanding
16,268
16,581
Price
5,280.00
-15.11%
6,220.00
-20.36%
Market cap
85,894,781
-16.71%
103,131,973
-17.26%
EV
97,677,498
120,570,098
EBITDA
31,047,951
29,726,634
EV/EBITDA
3.15
4.06
Interest
2,553,778
2,580,742
Interest/NOPBT
10.04%
10.45%